Pathios Therapeutics Ltd.

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up

Venture capital investment in biopharmaceutical companies ticked higher in the first quarter of 2024. In the second quarter, money is flowing into VC investors and funds focused specifically on the li

New biotech ThirtyFiveBio has emerged from stealth mode following a $20m seed financing as it advances a first-in-class G Protein-Coupled Receptor 35 (GPR35) antagonist approach for the treatment of